Granite Investment Partners, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.

Quarter-by-quarter ownership
Granite Investment Partners, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$32,708,865
+19.6%
856,253
+12.9%
1.37%
+25.7%
Q2 2023$27,345,316
+0.1%
758,118
+6.0%
1.09%
-4.3%
Q1 2023$27,315,283
-46.8%
715,247
-20.8%
1.14%
-46.7%
Q4 2022$51,373,986
+41.2%
902,882
-1.9%
2.14%
+35.2%
Q3 2022$36,392,000
-11.5%
920,380
-1.5%
1.58%
-7.8%
Q2 2022$41,101,000
+11.6%
934,110
+1.1%
1.71%
+37.0%
Q1 2022$36,829,000
-2.0%
923,507
-1.2%
1.25%
+13.9%
Q4 2021$37,579,000
+3.7%
934,562
+5.0%
1.10%
-2.7%
Q3 2021$36,221,000
-13.2%
890,396
-3.1%
1.13%
-12.4%
Q2 2021$41,733,000
+9.3%
919,029
+0.3%
1.29%
+1.3%
Q1 2021$38,191,000
-5.2%
916,064
-2.9%
1.27%
-9.9%
Q4 2020$40,305,000
+15.2%
943,682
-29.1%
1.41%
-9.0%
Q3 2020$34,975,000
+3.6%
1,330,847
+5.7%
1.55%
-4.6%
Q2 2020$33,745,000
+46.8%
1,258,681
-1.5%
1.62%
+9.1%
Q1 2020$22,981,000
-1.7%
1,277,438
-3.2%
1.49%
+35.3%
Q4 2019$23,389,000
+73.9%
1,319,176
+52.1%
1.10%
+58.0%
Q3 2019$13,453,000
-8.6%
867,396
+1.3%
0.70%
-11.8%
Q2 2019$14,716,000
-10.4%
856,563
-16.1%
0.79%
-15.3%
Q1 2019$16,433,000
+13.6%
1,020,695
+3.2%
0.93%
-11.9%
Q4 2018$14,468,000
+4.1%
988,939
+29.3%
1.06%
+32.2%
Q3 2018$13,902,000
+12.2%
765,103
+4.2%
0.80%
+1.9%
Q2 2018$12,391,000
-13.5%
734,528
+0.4%
0.78%
-18.1%
Q1 2018$14,332,000
-5.5%
731,636
-2.3%
0.96%
+0.1%
Q4 2017$15,171,000
+6.7%
748,809
-8.5%
0.96%
+8.3%
Q3 2017$14,217,000
+96.1%
818,505
+44.7%
0.88%
+80.8%
Q2 2017$7,250,000565,5070.49%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders